Three Forces Carrying Biotech into 2027

Three Forces Carrying Biotech into 2027

Key takeaways

  • AI is changing the economics of drug development. Practical applications are already helping companies reduce costs and accelerate research, with potentially greater benefits ahead.
  • China is expanding the global pool of promising science. More competition, but also more innovation—and a growing source of assets for pharmaceutical pipelines.
  • Biotech's fundamentals are improving faster than sentiment. Research spending, new medicines and deal-making are all picking up.

A Stronger Foundation for 2027

In recent months, we’ve spent lot of time with biotech management teams, attending conferences and meeting with companies and clients across the United States, Asia and beyond. Despite continued periods of volatility in biotech equities, what we've heard has reinforced our view that the industry is entering 2027 in a stronger position than it has been in for several years.

The US midterm elections and the latest sell-off in AI-related stocks have added to market uncertainty. But neither has materially changed what we're hearing from biotech companies or the fundamental developments shaping our outlook. Policy, financing conditions and valuations will remain important, but the underlying industry trends give us reason for optimism.

Three developments stand out. Artificial intelligence (AI) is beginning to change the economics of drug discovery and development. China's rapidly advancing biotech industry is expanding the global pool of promising science while raising the competitive bar. And capital is returning to research as new therapies advance and large pharmaceutical companies look to replenish their pipelines.

These are not simply long-term possibilities. We're already seeing evidence of change in how companies allocate research dollars, develop medicines and compete for capital. The implications extend well beyond the next product launch or clinical trial.

For investors, the question is whether share prices adequately reflect an industry whose ability to turn science into medicine is improving. In a number of cases, our analysis suggests they do not.

See more: AI: Where Will the Money Come From?